National Trends in Management of Newly Diagnosed Prostate Cancer.

[1]  I. Gill,et al.  Trends in Incidence of Metastatic Prostate Cancer in the US , 2022, JAMA network open.

[2]  M. Cooperberg,et al.  MP43-03 ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER: TIME TRENDS AND VARIATION IN THE AUA QUALITY (AQUA) REGISTRY , 2022, Journal of Urology.

[3]  D. Howard,et al.  Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer. , 2020, Urologic oncology.

[4]  H. Kume,et al.  Comparison of perioperative outcomes in elderly (age ≧ 75 years) vs. younger men undergoing robot-assisted radical prostatectomy , 2020, PloS one.

[5]  H. Lepor,et al.  Exploring Variation in the Use of Conservative Management for Low-risk Prostate Cancer in the Veterans Affairs Healthcare System. , 2020, European urology.

[6]  Jim C Hu,et al.  Trends in the Use of Stereotactic Body Radiotherapy for Treatment of Prostate Cancer in the United States. , 2020, JAMA network open.

[7]  M. Cooperberg,et al.  Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. , 2020, JAMA.

[8]  J. Dimick,et al.  Trends in the Adoption of Robotic Surgery for Common Surgical Procedures , 2020, JAMA network open.

[9]  J. Mohler,et al.  NCCN Guidelines Updates: Management of Prostate Cancer. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[10]  L. Holmberg,et al.  Radical Prostatectomy or Watchful Waiting in Prostate Cancer — 29-Year Follow-up , 2018, New England Journal of Medicine.

[11]  N. Magné,et al.  Comprehensive Geriatric Assessment and quality of life after localized prostate cancer radiotherapy in elderly patients , 2018, PloS one.

[12]  David C. Miller,et al.  Early effect of Medicare Shared Savings Program accountable care organization participation on prostate cancer care , 2018, Cancer.

[13]  T. Skolarus,et al.  Urologist Practice Affiliation and Intensity-modulated Radiation Therapy for Prostate Cancer in the Elderly. , 2017, European urology.

[14]  Mark S. Litwin,et al.  The Diagnosis and Treatment of Prostate Cancer: A Review , 2017, JAMA.

[15]  David Gillatt,et al.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. , 2017, The New England journal of medicine.

[16]  Issa J Dahabreh,et al.  Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidence. , 2016, International journal of epidemiology.

[17]  T. Daskivich,et al.  Questioning the 10-year Life Expectancy Rule for High-grade Prostate Cancer: Comparative Effectiveness of Aggressive vs Nonaggressive Treatment of High-grade Disease in Older Men With Differing Comorbid Disease Burdens. , 2016, Urology.

[18]  A. D'Amico,et al.  Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. , 2015, European urology.

[19]  Jean M. Mitchell.  Urologists' use of intensity-modulated radiation therapy for prostate cancer. , 2013, The New England journal of medicine.

[20]  John T. Wei,et al.  Use of advanced treatment technologies among men at low risk of dying from prostate cancer. , 2013, JAMA.

[21]  Anssi Auvinen,et al.  Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). , 2012, European urology.

[22]  N. Mottet,et al.  EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease - Guía de la EAU sobre el cáncer de próstata. Parte I: cribado, diagnóstico y tratamiento del cáncer clínicamente localizado , 2011 .

[23]  M. Cooperberg,et al.  Impact of age at diagnosis on prostate cancer treatment and survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. D'Amico,et al.  Guideline for the management of clinically localized prostate cancer: 2007 update. , 2007, The Journal of urology.

[25]  D. Lubeck,et al.  Assessment of prognosis with the total illness burden index for prostate cancer , 2007, Cancer.

[26]  M. Tinetti,et al.  The Effect of Age and Chronic Illness on Life Expectancy after a Diagnosis of Colorectal Cancer: Implications for Screening , 2006, Annals of Internal Medicine.

[27]  L. Chambless,et al.  Neighborhood of residence and incidence of coronary heart disease. , 2001, The New England journal of medicine.

[28]  J L Warren,et al.  Development of a comorbidity index using physician claims data. , 2000, Journal of clinical epidemiology.

[29]  R A Stephenson,et al.  Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. , 2000, JAMA.

[30]  Ronald C. Chen,et al.  Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men , 2018, JAMA oncology.

[31]  Sam S. Chang,et al.  Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer , 2017, JAMA surgery.

[32]  F. Montorsi,et al.  Clinical factors predicting late severe urinary toxicity after postoperative radiotherapy for prostate carcinoma: a single-institute analysis of 742 patients. , 2012, International journal of radiation oncology, biology, physics.

[33]  R. Weinberg,et al.  The watchman. , 2012, Annals of internal medicine.

[34]  C. Gross,et al.  The population level prevalence and correlates of appropriate and inappropriate imaging to stage incident prostate cancer in the medicare population. , 2012, The Journal of urology.